Akebia Therapeutics, Inc. can be found on NASDAQ as the akba stock price at https://www.webull.com/quote/nasdaq-akba  when looking for its share value. It was founded in the year 2007 and has its headquarters in Massachusetts. The average price of the stock is around 17.29 USD. It has a high estimate of 26.00 USD and a low estimate of 11 USD.

About the company

Akebia Therapeutics, Inc. is a company in the biopharmaceutical industry. The company primarily focuses on the commercialisation and development of products and therapeutics that are based on HIF “hypoxia-inducible factor” biology.

The leading product of the company is for the treatment of anaemia of those suffering from chronic kidney conditions. It is also involved in the development of vadadustat that can be used on oral therapy. Along with that, the company Is also involved in the development of a HIF based portfolio of candidate products that are aimed at serious diseases which relate to unmet needs.

About the stocks of Akebia Therapeutics

Recent studies and analysis have shown that right now would be a good time to invest or be a current investor in the Akebia Therapeutics and hold some stock of the same. The akba stock price has moved up and been higher by fifty-five per cent over only the past month.

Two prominent features show that the stock of the company might be on the right track and leading to success. This is a combination of strong and high price productivity and performance along with favourable technical.

This seems to be the case, according to finance experts if you take into consideration the recent estimation of the akba stock price and the predicted earnings estimation. From the looks of the same, the future of the company looks quite favourable and the company even earned the second rank (buy) on Zacks Rank. Last year the company generated global revenue of around $24 billion. By the end of 2020, it is predicted to reach soaring heights and reach around 77.6 billion.

Final words: 

This company that works with the inherent purpose of improving the lives of those who are suffering from a kidney disease announced on the 20th of May 2020 that the underwriters of their previously offered public offerings which is said to have closed on the 14th have exercised their option to purchase an additional amount of 1,650,000 shares to the full. This was from its common stock which was offered for 12 dollars per share with a lesser amount of underwriting truths as well as commissions.

After making evident the option to the shareholders of closing at full the number of shares sold by the company saw an overall increase in the number of shares sold as the numbers reached around 12,650,000 shares.  You can also check bapr news at https://www.webull.com/quote/bats-bapr .